Medpace Holdings, Inc.

Is Medpace Holdings, Inc. overvalued or undervalued?

As of September 3, 2025, Medpace Holdings, Inc. is considered very expensive with a high P/E ratio of 21 compared to peers, despite strong returns, indicating it may be overvalued at its current price of 501.94.

As of 3 September 2025, the valuation grade for Medpace Holdings, Inc. has moved from expensive to very expensive, indicating a significant concern regarding its valuation. The company appears to be overvalued, particularly when considering its P/E ratio of 21, which is notably higher than peers such as ICON plc with a P/E of 14.64 and Booz Allen Hamilton Holding Corp. at 15.81. Additionally, Medpace's EV to EBITDA ratio stands at 16.73, again exceeding the industry averages, which raises further doubts about its current valuation.<BR><BR>In comparison to the S&P 500, Medpace has shown impressive returns, with a YTD return of 51.08% compared to the index's 12.22%, and a remarkable 3Y return of 232.70% against 70.41% for the S&P 500. However, despite these strong performance metrics, the high valuation ratios suggest that the stock may not be a sustainable investment at its current price of 501.94.

Is Medpace Holdings, Inc. technically bullish or bearish?

As of July 31, 2025, Medpace Holdings, Inc. shows a bullish technical trend with strong momentum indicators, despite some mixed signals in the KST and OBV, and has significantly outperformed the S&P 500 year-to-date and over three years.

As of 31 July 2025, the technical trend for Medpace Holdings, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, and both the Bollinger Bands and Dow Theory confirm a bullish stance across these time frames. Daily moving averages also indicate bullish momentum. However, the KST is bullish on a weekly basis but mildly bearish monthly, and the OBV shows a mildly bearish trend over the month. <BR><BR>Medpace has significantly outperformed the S&P 500, with a year-to-date return of 51.08% compared to the S&P 500's 12.22%, and a three-year return of 232.70% versus 70.41% for the benchmark. Overall, the current technical stance is bullish, reflecting strong momentum despite some mixed signals in the KST and OBV.

How big is Medpace Holdings, Inc.?

As of Jun 18, Medpace Holdings, Inc. has a market capitalization of $8.58 billion, with net sales of $2.16 billion and net profit of $416.39 million over the last four quarters.

As of Jun 18, Medpace Holdings, Inc. has a market capitalization of 8,583.58 million, categorizing it as a Mid Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 2,156.58 million, while the sum of Net Profit for the same period is 416.39 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds of 825.54 million and Total Assets of 2,100.87 million.

What does Medpace Holdings, Inc. do?

Medpace Holdings, Inc. is a clinical contract research organization that offers drug and medical device development services. As of March 2025, it reported net sales of $559 million and a net profit of $115 million, with a market cap of approximately $8.58 billion.

Overview: <BR>Medpace Holdings, Inc. is a clinical contract research organization that provides clinical research-based drug and medical device development services, operating within the Miscellaneous industry and classified as a Mid Cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 559 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 115 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 8,583.58 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 21.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.70 <BR>Return on Equity: 70.14% <BR>Price to Book: 14.46<BR><BR>Contact Details: <BR>Address: 5375 Medpace Way, CINCINNATI OH: 45227-1543 <BR>Tel: 1 513 5799911 <BR>Website: http://investor.medpace.com/investor-overview

Should I buy, sell or hold Medpace Holdings, Inc.?

Who are in the management team of Medpace Holdings, Inc.?

As of March 2022, the management team of Medpace Holdings, Inc. includes Dr. August Troendle (Chairman, President, CEO), Mr. Fred Davenport (Lead Independent Director), and independent directors Mr. Brian Carley, Ms. Ashley Keating, Dr. Thomas King, and Mr. Robert Kraft.

As of March 2022, the management team of Medpace Holdings, Inc. includes Dr. August Troendle, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features Mr. Fred Davenport as the Lead Independent Director, along with independent directors Mr. Brian Carley, Ms. Ashley Keating, Dr. Thomas King, and Mr. Robert Kraft. <BR><BR>In summary, as of March 2022, the management team consists of Dr. August Troendle, Mr. Fred Davenport, Mr. Brian Carley, Ms. Ashley Keating, Dr. Thomas King, and Mr. Robert Kraft.